Rznomics Inc.
@rznomics.com
Rznomics is developing safe and effective biopharmaceuticals in oncology, degenerative disease, and genetic disease based on RNA platform technology called trans-splicing ribozyme. Acknowledged by bio-focused institutions, Rznomics has raised \23.7 billion from series A& B and recently raised \37.2 billion from series C, resulting in a total of \60.9 billion of fundraising. Also, Rznomics received \8 billion for the new drug development research funding from the government. In 2022 1H, Rznomics’ RZ-001 IND submission for the HCC treatment was approved by MFDS, and the clinical trial for the RZ-001 is currently running. In addition to the RZ-001, Rznomics has competitive and innovative pipelines, such as glioblastoma multiforme, Alzheimer’s disease, genetic ocular disease (retinitis pigmentosa), and circular RNA technology. Rznomics is also actively partnering with global companies to discuss collaboration opportunities in co-research, co-development, and licensing. Rznomics entered global licensing agreement with Eli Lilly for RNA-editing Therapeutics in May 2025, and was listed on KOSDAQ market in Dec 2025.
Rznomics Inc.'s Company Logos
Rznomics Inc.'s Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#FF0000
Red
255, 0, 0
0, 100, 50
0, 100, 100, 0
#B4C8E3
Periwinkle Gray
180, 200, 227
214, 46, 80
21, 12, 0, 11
#003975
Regal Blue
0, 57, 117
211, 100, 23
100, 51, 0, 54
About Rznomics Inc.
Rznomics is a brand that specializes in RNA technology, offering innovative solutions for unmet medical needs. They are at the forefront of the industry with their molecule dual function Modular Engineering and High Performance RNA platform. Rznomics is dedicated to addressing the challenges of the healthcare field by developing cutting-edge therapies and drugs.
Their extensive pipeline includes RZ-001, RZ-002, RZ-003, and RZ-004, which are geared towards meeting unmet medical needs. With a focus on excellence in technology, Rznomics excels in the field of RNA research and development. They strive to provide solutions that push the boundaries of medical advancements and improve patients' lives.
Stay updated with the latest news and press releases from Rznomics to learn more about their RNA platform and advancements in the field. Contact them for more information or explore their website for a comprehensive overview of their offerings. Rznomics is a leading brand in the field of RNA technology, committed to revolutionizing healthcare and making a significant impact on the medical industry
Brand industry
Science and Education
Company type
Privately Held
Year founded
2017
Company size
11-50 employees
